“I would like to highlight here the growing interest in radiopharmaceuticals where we are well positioned. Novartis confirms the commitment to build on its late-stage radioligand portfolio and they are going further with Lutathera in Phase III.” q3 2020
“We are very pleased to see all of that because that really helps us also to create the awareness of radiopharmaceuticals with health care providers, with payers and so on and so forth and policymakers, of course. So all of that, I think, is a very, very good signal that there is a growing interest in radiopharmaceuticals.” q3 2020
Nieba namedroppa vel Novartis i anledning samarbeid i satsing og policy rundt radioligand terapi som et likeverdig behandlingsalternativ ved et par anledninger i forbindelse med Q3 2020 og DNB Healthcare 2020 i desember i fjor.
“Within this project, an international framework (the Radioligand Therapy Readiness Assessment Framework) has been assembled to assess health system readiness for the use of radioligand therapy and to identify policy changes that could facilitate appropriate integration of this innovative cancer treatment modality.”
“Changes within healthcare system infrastructures are needed to improve the availability of these innovative therapies.”
“Marco Renoldi, Nordic Nanovector’s Chief Operating Officer, said: “Nordic Nanovector is proud to support this important initiative, which is part of ongoing efforts to positively change the healthcare landscape and improve appropriate clinical adoption of radioligand therapies. This modality has demonstrated promising clinical efficacy and tolerability in a wide range of cancer types, including neuroendocrine neoplasms, lymphoma and prostate cancer, where there is still a significant unmet need. Our own candidate is among a growing pipeline of novel radioligand therapies that are progressing through clinical development. It is important that eligible patients have access to these targeted and well-tolerated therapies given their potential benefits and once they are approved, this framework will be crucial to helping prepare healthcare systems for their appropriate use.””
Og som @InVivo nevner
Dette er da hjertebarnet Nieba snakket om i fjor, sannelig pent at det blir løftet frem.
Nordic Nanovector is swinging with the big dicks og er sannelig en “emerging leader in cancer care”!
Hold på bukseselene, dette kan ta av ganske så fort.
Ikke sprett champagnen helt enda 
